334 related articles for article (PubMed ID: 27074921)
1. Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis.
Mendel I; Yacov N; Shoham A; Ishai E; Breitbart E
Dig Dis Sci; 2016 Sep; 61(9):2545-53. PubMed ID: 27074921
[TBL] [Abstract][Full Text] [Related]
2. Treatment with lecinoxoids attenuates focal and segmental glomerulosclerosis development in nephrectomized rats.
Yacov N; Feldman B; Volkov A; Ishai E; Breitbart E; Mendel I
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):131-143. PubMed ID: 30125459
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
4. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
7. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
8. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
9. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
11. Chronic ethanol consumption plus an atherogenic diet cause metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice.
Liu J; Oba Y; Yamano S
Alcohol Clin Exp Res; 2022 Jul; 46(7):1192-1203. PubMed ID: 35491473
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE⁻/⁻ mice.
Feige E; Yacov N; Salem Y; Levi I; Mendel I; Propheta-Meiran O; Shoham A; Hait-Darshan R; Polonsky O; George J; Harats D; Breitbart E
Atherosclerosis; 2013 Aug; 229(2):430-9. PubMed ID: 23880199
[TBL] [Abstract][Full Text] [Related]
13. Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells.
Cheng Y; Chen T; Ping J; Chen J
Cell Physiol Biochem; 2018; 48(3):971-982. PubMed ID: 30036865
[TBL] [Abstract][Full Text] [Related]
14. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
16. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
17. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet.
Luo XY; Takahara T; Kawai K; Fujino M; Sugiyama T; Tsuneyama K; Tsukada K; Nakae S; Zhong L; Li XK
Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(12):G891-9. PubMed ID: 24136786
[TBL] [Abstract][Full Text] [Related]
18. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
19. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]